Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor

Brain Research Bulletin

Volumn 98, Issue , 2013, Pages 122-131

  Hammer, Leslie A ^a   Zagon, Ian S ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Astrogliosis; Inflammation; Microglial proliferation; Opioid growth factor; Relapse remitting experimental autoimmune encephalomyelitis; Spinal cord

Indexed keywords

GROWTH FACTOR; OPIOID GROWTH FACTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; DNA SYNTHESIS; HISTOPATHOLOGY; IMMUNIZATION; LUMBAR SPINAL CORD; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE;

ASTROGLIOSIS; INFLAMMATION; MICROGLIAL PROLIFERATION; OPIOID GROWTH FACTOR; RELAPSE-REMITTING EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SPINAL CORD;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; LAMENESS, ANIMAL; LOCOMOTION; MICE; MOTOR NEURONS; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; PSYCHOMOTOR PERFORMANCE; RECEPTORS, OPIOID; RECURRENCE; SEVERITY OF ILLNESS INDEX; SPINAL CORD; T-LYMPHOCYTES; TIME FACTORS;

EID: 84883807807     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2013.08.001     Document Type: Article

References (39)

1. Bannerman P., Hahn A., Soulika A., Gallo V., Pleasure D. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia 2007, 55:57-64.
2. Bennett J.L., Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin. Neuropharmacol. 2009, 32:121-132.
3. Campbell A.M., Zagon I.S., McLaughlin P.J. Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis. Brain Res. 2012, 1472:138-148.
4. Campbell A.M., Zagon I.S., McLaughlin P.J. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis. Brain Res. Bull. 2013, 90:43-51.
5. 5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. Am. J. Physiol. 2010, 299:R774-R785.
6. WAF1/CIP1 pathways to restrict normal cell proliferation. Mol. Biol. Cell 2009, 20:319-327.
7. Chiba K., Kataoka H., Seki N., Shimano K., Koyama M., Fukunari A., Sugahara K., Sugita T. Fingolimod (FTY720), sphingosine-1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. Int. Immunopharmacol. 2011, 11:366-372.
8. Cree B.A., Kornyeyeva E., Goodin D.S. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann. Neurol. 2010, 68:145-150.
9. Devonshire V., Havrdova E., Radue E.W., O'Connor P., Zhang-Auberson L., Agoropoulou C., Haring D.A., Francis G., Kappos L. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012, 11:386-388. FREEDOMS Study Group.
10. Fitzner D., Simons M. Chronic progressive multiple sclerosis-pathogenesis of neurodegeneration and therapeutic strategies. Curr. Neuropharmacol. 2010, 8:305-315.
11. Gironi M., Martinelli V., Brambilla E., Furlan R., Panerai A.E., Comi G., Sacerdote P. β-Endorphin concentrations in peripheral blood mononuclear cells of patients with multiple sclerosis. Arch. Neurol. 2000, 57:178-1181.
12. Gourdain P., Barrerini C., Nicoit A.B., Carnaud C. Exacerbation of experimental autoimmune encephalomyelitis in prion protein (Pt/Pc)-null mice evidence for a critical role of the central nervous system. J. Neuroinflamm. 2012, 9:25.
13. Horga A., Tintore M. Natalizumab for relapsing-remitting multiple sclerosis. Neurologia 2011, 26:357-368.
14. Jackson S.J., Lee J.E., Nikodemova M., Fabry Z., Duncan I.D. Quantification of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. J. Neuropathol. Exp. Neurol. 2009, 68:616-625.
15. Jankovic B.D. Enkephalins and immune inflammatory reactions. Acta Neurol. (Napoli) 1991, 13:433-441.
16. Jasmin L., Janni G., Moallem T.M., Lappi D.A., Ohara P.T. Schwann cells are removed from the spinal cord after effecting recovery from paraplegia. J. Neurosci. 2000, 20:9215-9223.
17. Mangano K., Nicoletti A., Patti F., Donia M., Malaguarnera L., Signorelli S., Magro G., Muzio V., Greco B. Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clin. Exp. Immunol. 2009, 159:159-168.
18. McCandless E.E., Wang Q.I., Woerner B.M., Harper J.M., Klein Harper R.S. CSCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:8053-8064.
19. McLaughlin P.J., Zagon I.S. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulation of cell proliferation and its implications for health and disease. Biochem. Pharmacol. 2012, 84:746-755.
20. Miller S.D., Karpus W.J. Experimental autoimmune encephalomyelitis in the mouse. Curr. Protoc. Immunol. 2007, Chapter 15.
21. National Multiple Sclerosis Society, 2013. http://www.nationalmssociety.org/about-the-society/ms-prevalence/index.aspx.
22. Pollinger B., Krishnamoorthy G., Berer K., Lassmann H., Bosl M.R., Dunn R., Domingues H.S., Holz A., Kurschus F.C., Wekerle H. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J. Exp. Med. 2009, 206:1303-1316.
23. Rahn K.A., McLaughlin P.J., Zagon I.S. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis. Brain Res. 2011, 1381:243-253.
24. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell Physiol. 2000, 182:311-322.
25. Shafri M.A.M., Matjais A.M., Jaffri J., Kim N.K., Ithnin H., Mohamed F. Cresyl violet staining to assess neuroprotective and neurodegenerative effects of haruan traditional extract against neurodegenerative damage of ketamine. Int. J. Pharmacy Pharmaceut. Sci. 2012, 4:163-168.
26. Sharafaddinzadeh N., Moghtaderi A., Kashipazha D., Majdinasab N., Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult. Scler. 2010, 16:964-969.
27. Stoll S.S., Nieves C., Tabby D.S., Schwartzman R. Use of therapies other than disease-modifying agents, including complementary and alternative medicine, by patients with multiple sclerosis: a survey study. J. Am. Osteopath. Assoc. 2012, 112:22-28.
28. Summers De Luca L.E., Pikor N.B., O'Leary J., Galicia-Rosas G., Ward L.A., Defreitas D., Finaly T.M., Ousman S.S., Osborne L.R., Gommerman J.L. Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis. J. Immunol. 2010, 184:3174-3185.
29. Ulrich R., Baumgartner W., Gerhauser I., Seeliger F., Haist V., Deschl U., Alldinger S. MMP-12, MMP-3, and TIMP-1 are markedly upregulated in chronic demyelinating Theiler murine encephalomyelitis. J. Neuropathol. Exp. Neurol. 2006, 65:783-793.
30. Venkatesan C., Chizaszcz M.A., Choi N., Wainwright M.S. Chronic upregulation of activated microglia immunoreactive for galectin-3/Max-2 and nerve growth factor following diffuse axonal injury. J. Neuroinflamm. 2010, 7:32.
31. Weir C., McNeill A., Hook S., Harvie M., La Flamme A.C., Le Gros G., Backstrom T. Critical role of preproenkephalin in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2006, 179:18-25.
32. Zagon I.S., Donahue R.N., McLaughlin P.J. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am. J. Physiol. 2009, 297:R1154-R1161.
33. 5]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiology 2011, 216:579-590.
34. Zagon I.S., Donahue R.N., Bonneau R.H., McLaughlin P.J. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology 2011, 216:173-183.
35. Zagon I.S., Rahn K.A., Bonneau R.H., Turel A.P., McLaughlin P.J. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res. 2010, 1310:154-161.
36. Zagon I.S., Rahn K.A., Turel A.P., McLaughlin P.J. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp. Biol. Med. 2009, 234:1383-1392.
37. Zagon I.S., Verderame M.F., McLaughlin P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res. Rev. 2002, 38:351-376.
38. Ziaber J., Baj Z., Pasnik J., Chmielewski H., Tchorzewski H. Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple sclerosis. Immunol. Lett. 2000, 71:127-129.
39. Ziaber J., Panik J., Baj Z., Pokoca L., Chmielewski H., Tchorzewski H. The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis. Mediators Inflamm. 1999, 7:335-338.